GRI Bio participates in virtual investor KOL Connect segment

GRI Bio announced its participation in a recent Virtual Investor KOL Connect segment. As part of the segment, Albert Agro, PhD, Chief Medical Officer of GRI Bio and Dr. Helen Parfrey, Respiratory Consultant at Royal Papworth Hospital and Affiliated Assistant Professor at the University of Cambridge, discuss IPF, the current patient journey, and how the Company is working to advance their lead program, GRI-0621, as a potential therapeutic solution that halts disease progression of fibrotic diseases such as IPF. IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream. Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance and no impact on overall survival1 leaving significant opportunity to augment IPF treatment with a new therapeutic. GRI Bio’s lead program, GRI-0621, is a small molecule RAR-beta dual agonist that inhibits the activity of human iNKT cells. In preliminary trials to date and previous trials with the oral formulation, GRI-0621 has been shown to improve fibrosis in multiple disease models and improve liver function tests and other markers of inflammation and injury in patients. GRI-0621 is currently being evaluated in a Phase 2a biomarker study and expects to report interim data in Q4 2024 and topline data in Q1 2025.